Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs

Blood

Volumn 123, Issue 25, 2014, Pages 3943-3950

  Duek, Adrian ^a   Lundberg, Pontus ^a   Shimizu, Takafumi ^a   Grisouard, Jean ^a   Karow, Axel ^a   Kubovcakova, Lucia ^a   Hao Shen, Hui ^a   Dirnhofer, Stephan ^b   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; JANUS KINASE 2; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; BURST FORMING UNIT E; CELL DIFFERENTIATION; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; GENE DELETION; GRAFT RECIPIENT; IN VIVO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MICROENVIRONMENT; MOUSE; MOUSE MODEL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REDUCTION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; TRANSCRIPTION INITIATION; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; BONE MARROW NEOPLASMS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; ERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON-GAMMA; JANUS KINASE 2; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; POLYCYTHEMIA VERA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT1 TRANSCRIPTION FACTOR; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPOIESIS;

EID: 84902669989     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-514208     Document Type: Article

References (30)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
3. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
4. Baxter EJ, Scott LM, Campbell PJ, et al Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
5. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
6. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6(11):627-637.
7. Van Etten RA, Koschmieder S, Delhommeau F, et al. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 2011;96(4):590-601.
8. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4(3):311-317.
9. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108(7):2435-2437. (Pubitemid 44497530)
10. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
11. Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18(5):524-535.
12. Huang Z, Richmond TD, Muntean AG, Barber DL, Weiss MJ, Crispino JD. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. J Clin Invest. 2007;117(12):3890-3899. (Pubitemid 350224098)
13. Penta K, Sawyer ST. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem. 1995;270(52):31282-31287. (Pubitemid 26012216)
14. Halupa A, Bailey ML, Huang K, Iscove NN, Levy DE, Barber DL. A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. Blood. 2005;105(2):552-561. (Pubitemid 40070736)
15. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84(3):443-450. (Pubitemid 26058569)
16. Göthert JR, Gustin SE, Hall MA, et al. In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood. 2005;105(7):2724-2732. (Pubitemid 40446262)
17. de Boer J, Williams A, Skavdis G, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol. 2003;33(2):314-325. (Pubitemid 36267595)
18. Pronk CJ, Rossi DJ, Månsson R, et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 2007;1(4):428-442. (Pubitemid 47506534)
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
20. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
21. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
22. Godfrey AL, Chen E, Pagano F, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120(13):2704-2707.
23. Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, Wojchowski DM. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest. 2006;116(3):683-694. (Pubitemid 43326877)
24. Porpiglia E, Hidalgo D, Koulnis M, Tzafriri AR, Socolovsky M. Stat5 signaling specifies basal versus stress erythropoietic responses through distinct binary and graded dynamic modalities. PLoS Biol. 2012;10(8):e1001383.
25. Yan D, Hutchison RE, Mohi G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood. 2012;119(15):3539-3549.
26. Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 2012;119(15):3550-3560.
27. Takayama M, Fujita R, Suzuki M, et al. Genetic analysis of hierarchical regulation for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis. Mol Cell Biol. 2010;30(11):2668-2680.
28. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(9):2867-2875. (Pubitemid 29200777)
29. Tsuji-Takayama K, Tahata H, Harashima A, et al. Interferon-gamma enhances megakaryocyte colony-stimulating activity in murine bone marrow cells. J Interferon Cytokine Res. 1996;16(9):701-708. (Pubitemid 26330416)
30. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90(11):4369-4383. (Pubitemid 27508443)